PMID- 21796254
OWN - NLM
STAT- MEDLINE
DCOM- 20111123
LR  - 20240511
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 7
DP  - 2011
TI  - Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel 
      in Chinese patients with percutaneous coronary intervention.
PG  - 399-404
LID - 10.2147/VHRM.S22273 [doi]
AB  - BACKGROUND: The purpose of this study was to examine the effect of proton pump 
      inhibitors (PPI) on the antiplatelet activity of clopidogrel in a consecutive 
      series of Chinese patients after they had received coronary stents. METHODS: A 
      sample of 51 consecutive Chinese patients treated with coronary stents and taking 
      PPI and clopidogrel for more than 30 days were enrolled in this study. Mean 
      values for platelet residual units and percentage inhibition before PPI (+PPI) 
      and 14 days after discontinuation of PPI (-PPI) were compared using the paired 
      t-test. RESULTS: There was no effect of concomitant use of esomeprazole and 
      clopidogrel or omeprazole and clopidogrel on the inhibition assay, but platelet 
      residual units and percentage inhibition showed statistically significant 
      improvement after stopping lansoprazole in Chinese patients who were on chronic 
      clopidogrel therapy. Clopidogrel resistance existed more frequently in the 
      Chinese-American population examined, and was as high as 68% (+PPI) to 73% 
      (-PPI). CONCLUSION: The clopidogrel resistance found is cause for concern, 
      although its relationship with clinical events is currently unknown in this 
      population. Further study with other thienopyridines or genetic variant analysis 
      is suggested.
FAU - Kwan, Joanne
AU  - Kwan J
AD  - Boston University, Boston, MA, USA.
FAU - Htun, Wah Wah
AU  - Htun WW
FAU - Huang, Yili
AU  - Huang Y
FAU - Ko, Wilson
AU  - Ko W
FAU - Kwan, Tak W
AU  - Kwan TW
LA  - eng
PT  - Journal Article
DEP - 20110624
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - A74586SNO7 (Clopidogrel)
RN  - KG60484QX9 (Omeprazole)
RN  - N3PA6559FT (Esomeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angioplasty, Balloon, Coronary/adverse effects/instrumentation
MH  - Asian
MH  - *Asian People
MH  - Blood Platelets/drug effects
MH  - China/ethnology
MH  - Clopidogrel
MH  - Drug Resistance
MH  - Esomeprazole
MH  - Female
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - New York City/epidemiology
MH  - Omeprazole/*therapeutic use
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Stents
MH  - Thrombosis/blood/ethnology/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
MH  - Time Factors
PMC - PMC3141912
OTO - NOTNLM
OT  - Chinese population
OT  - clopidogrel resistance
OT  - percutaneous coronary intervention
OT  - proton pump inhibitors
EDAT- 2011/07/29 06:00
MHDA- 2011/12/13 00:00
PMCR- 2011/06/24
CRDT- 2011/07/29 06:00
PHST- 2011/06/24 00:00 [received]
PHST- 2011/07/29 06:00 [entrez]
PHST- 2011/07/29 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2011/06/24 00:00 [pmc-release]
AID - vhrm-7-399 [pii]
AID - 10.2147/VHRM.S22273 [doi]
PST - ppublish
SO  - Vasc Health Risk Manag. 2011;7:399-404. doi: 10.2147/VHRM.S22273. Epub 2011 Jun 
      24.